ETON PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.59 USD | -0.28% |
|
0.00% | -17.35% |
| May. 09 | Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | 36.1M | Sales 2025 * | 47.4M | Capitalization | 92.48M |
|---|---|---|---|---|---|
| Net income 2024 * | -1M | Net income 2025 * | 7M | EV / Sales 2024 * | 2.56 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.95 x |
| P/E ratio 2024 * |
-60
x | P/E ratio 2025 * |
13.3
x | Employees | 30 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eton Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -1.64% | ||
| 1 week | -1.37% | ||
| Current month | +2.86% | ||
| 1 month | +9.76% | ||
| 3 months | -19.46% | ||
| 6 months | -1.10% | ||
| Current year | -17.81% |
1 week
3.50
3.75
1 month
3.113.92
Current year
3.035.11
1 year
2.425.81
3 years
1.958.85
5 years
1.9510.30
10 years
1.9510.30
| Managers | Title | Age | Since |
|---|---|---|---|
Sean Brynjelsen
CEO | Chief Executive Officer | 52 | 17-05-31 |
James Gruber
DFI | Director of Finance/CFO | 52 | 22-04-10 |
Lisa M. Wilson
IRC | Investor Relations Contact | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 17-05-31 | |
Paul Maier
BRD | Director/Board Member | 76 | 17-09-13 |
Norbert Riedel
CHM | Chairman | 66 | 17-09-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 3.6 | 0.00% | 221 252 |
| 24-05-23 | 3.6 | -1.64% | 22,897 |
| 24-05-22 | 3.66 | +1.95% | 62,268 |
| 24-05-21 | 3.59 | -1.37% | 25,697 |
| 24-05-20 | 3.64 | +0.55% | 83,827 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.
Sector
Pharmaceuticals
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.6
USD
Average target price
8
USD
Spread / Average Target
+122.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.81% | 92.48M | |
| +8.35% | 8.79B | |
| -15.14% | 4.88B | |
| +50.73% | 4.73B | |
| +4.36% | 3.92B | |
| -26.13% | 2.2B | |
| +12.74% | 2.28B | |
| +16.45% | 2.11B | |
| -33.59% | 2.08B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- ETON Stock
